Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 2/20 | 0.63 |
| ▸ | NAMPT | P43490 | 1/20 | 0.63 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.63 |
| ▸ | DGAT2 | Q96PD7 | 8/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | MTOR | P42345 | 2/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 2/20 | 0.32 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18541417 | 1.00 | PAK4 (0.63) | PAK4NAMPTPAK1DGAT2MGLL | |
| SCHEMBL18541418 | 0.94 | PAK4 (0.71) | PAK4NAMPTPAK1DGAT2PIK3CA | |
| SCHEMBL18529787 | 0.94 | PAK4 (0.71) | PAK4NAMPTPAK1DGAT2PIK3CA | |
| SCHEMBL18541426 | 0.91 | PAK4 (0.63) | PAK4NAMPTPAK1DGAT2JAK2 | |
| SCHEMBL18529734 | 0.91 | PAK4 (0.63) | PAK4NAMPTPAK1DGAT2MGLL | |
| SCHEMBL18529768 | 0.91 | PAK4 (0.63) | PAK4NAMPTPAK1DGAT2JAK2 | |
| SCHEMBL18541423 | 0.90 | PAK4 (0.66) | PAK4NAMPTPAK1DGAT2 | |
| SCHEMBL18541332 | 0.90 | PAK4 (0.66) | PAK4NAMPTPAK1DGAT2 | |
| SCHEMBL18541419 | 0.88 | NAMPT (0.63) | PAK4NAMPTPAK1DGAT2ABL1 | |
| SCHEMBL18529799 | 0.88 | NAMPT (0.63) | PAK4NAMPTPAK1DGAT2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180244660-A1 | CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS | Karyopharm Therapeutics Inc. | 2018-08-30 | — | — | US | disclosed |
| WO-2017031204-A1 | CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS | Karyopharm Therapeutics Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017031204-A1 | CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS | Karyopharm Therapeutics Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244660-A1 | CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS | MALT1, BCL9, IKBKE | PAK4 265/4885NAMPT 2565/4885PAK1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.